Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1144588 | 1.00 | LMNA (0.57) | LMNAALDH1A1HCAR2POLBSMN1; SMN2 | |
| SCHEMBL1144606 | 0.87 | MAPT (0.50) | LMNAALDH1A1SMN1; SMN2GAAKMT2A | |
| SCHEMBL1144604 | 0.87 | MAPT (0.50) | LMNAALDH1A1SMN1; SMN2GAAKMT2A | |
| SCHEMBL8227037 | 0.87 | MAPT (0.50) | LMNAALDH1A1SMN1; SMN2GAAKMT2A | |
| SCHEMBL7689096 | 0.85 | GAA (0.42) | LMNAALDH1A1HCAR2POLBMAPK1 | |
| SCHEMBL7685591 | 0.83 | PARP1 (0.47) | LMNAALDH1A1SMN1; SMN2GAAKMT2A | |
| SCHEMBL7685587 | 0.83 | PARP1 (0.47) | LMNAALDH1A1SMN1; SMN2GAAKMT2A | |
| SCHEMBL7382477 | 0.80 | TDP1 (0.37) | LMNAALDH1A1HCAR2POLBSMN1; SMN2 | |
| SCHEMBL10982031 | 0.80 | TDP1 (0.37) | LMNAALDH1A1HCAR2POLBSMN1; SMN2 | |
| SCHEMBL7382480 | 0.80 | TDP1 (0.37) | LMNAALDH1A1HCAR2POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1386901-B1 | Method for producing an optically active beta-amino acid | TAKASAGO PERFUMERY CO LTD (JP) | 2015-07-01 | — | — | EP | disclosed |
| US-7893296-B2 | Method for producing an optically active β-amino acid | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-02-22 | — | — | US | disclosed |
| US-20060122418-A1 | Method for producing an optically active beta-amino acid | MATSUMURA KAZUHIKO | 2006-06-08 | — | — | US | disclosed |
| US-7015348-B2 | Method for producing an optically active β-amino acid | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-03-21 | — | — | US | disclosed |
| US-20040023344-A1 | Method for producing an optically activ beta-amino acid | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-02-05 | — | — | US | disclosed |
| EP-1386901-A1 | Method for producing an optically active beta-amino acid | Takasago International Corporation (JP) | 2004-02-04 | — | — | EP | disclosed |
| US-6376521-B1 | ANTIINFLAMMATORY AGENTS; ANTIISCHEMIC AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2002-04-23 | — | — | US | disclosed |
| WO-2000002861-A1 | A3 ADENOSINE RECEPTOR ANTAGONISTS | THE UNITED STATES OF AMERICA, REPRESENTED BY SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122418-A1 | Method for producing an optically active beta-amino acid | AADAT, DAO, BCAT2 | LMNA 2333/4885ALDH1A1 784/4885HCAR2 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.